Human Genome Sciences, Inc. (JOBS), GlaxoSmithKline Report Progress With Lupus Treatment

Bookmark and Share

WSJ -- Human Genome Sciences Inc. (HGSI) and GlaxoSmithKline PLC (GSK) reported progress in two Phase III trials of belimumab, under investigation as a treatment for seropositive patients with systemic lupus. The drug "plus standard of care achieved a clinically and statistically significant improvement in patient response rate" compared with placebo plus standard of care, the companies, based in Rockville, Md., and London, respectively, said in a statement on Tuesday.

Back to news